SV
SVRA.US Savara Inc
- Market cap
- USD 981M
- P/E
- -
- P/B
- 9.48x
- ROE
- -149.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SVRA.US undervalued?
Graham numberThe Graham number of Savara Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Savara Inc fundamental analysis
No fundamental analysis for Savara Inc yet.
Savara Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Full company profileSavara Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Savara Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 400K | 0.00 | 0.00 | 0.00 | 257K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 400K | -363K | -526K | -38.8M | -34.8M | -29.0M | -27.9M | -44.3M | -78.0M | -245K | - |
| Operating Income | -10.9M | -30.0M | -70.0M | -79.0M | -49.3M | -41.5M | -38.8M | -60.0M | -103M | -124M | -165M |
| EBITDA | -10.5M | -31.9M | -69.5M | -49.7M | -45.4M | -40.3M | -37.9M | -59.1M | -102M | -119M | -160M |
| Net Income | -10.9M | -29.8M | -61.5M | -78.2M | -49.6M | -43.0M | -38.2M | -54.7M | -95.9M | -119M | -161M |
| EPS | -3.27 | -1.70 | -1.85 | -1.95 | -0.84 | -0.32 | -0.25 | -0.33 | -0.48 | -0.53 | -0.63 |
| Balance Sheet | |||||||||||
| Total Assets | 28.9M | 160M | 152M | 136M | 97.7M | 177M | 140M | 178M | 213M | 253M | 156M |
| Total Liabilities | 64.8M | 40.3M | 152M | 34.5M | 33.4M | 32.1M | 32.0M | 37.2M | 41.4M | 50.3M | 48.1M |
| Shareholders' Equity | -35.9M | 119M | 108M | 102M | 64.4M | 144M | 108M | 140M | 171M | 203M | 108M |
| Cash & Short-term Investments | 13.4M | 94.3M | 111M | 122M | 82.2M | 161M | 126M | 162M | 196M | 236M | 130M |
| Total Debt | 4.47M | 15.3M | 24.6M | 25.6M | 25.3M | 25.8M | 26.1M | 26.5M | 26.7M | 29.9M | 31.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.37M | -28.2M | -39.3M | -45.1M | -39.8M | -40.1M | -34.6M | -51.1M | -89.1M | -101M | -140M |
| Capital Expenditure | 8.00K | 495K | 141K | 148K | 3.29M | 57.0K | 9.00K | 296K | 25.0K | 22.0K | 839K |
| Free Cash Flow | -8.38M | -28.7M | -39.4M | -45.3M | -43.1M | -40.1M | -34.6M | -51.4M | -89.1M | -101M | -141M |
| Ratios | |||||||||||
| ROE | - | -25.0% | -56.8% | -76.9% | -77.1% | -29.8% | -35.4% | -39.0% | -55.9% | -58.5% | -149.0% |
| ROA | -37.8% | -18.7% | -40.4% | -57.4% | -50.8% | -24.4% | -27.3% | -30.8% | -45.0% | -46.9% | -103.0% |
| Net Profit Margin | -2,730.8% | - | - | - | -19,305.4% | -4,301,400.0% | - | - | - | - | - |
| Debt to Equity | - | 0.13x | 0.23x | 0.25x | 0.39x | 0.18x | 0.24x | 0.19x | 0.16x | 0.15x | 0.29x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Savara Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 2.12M | 0.04 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:70 on Apr 28, 2017.
Who owns Savara Inc
- Insiders 2.38%
- Institutions 97.62%
- Public & others 0.00%
- Shares outstanding 221M
- Free float 145M
Top funds holding SVRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Polar Capital Healthcare Opports Inc | 8.19M | 3.99% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 6.16M | 3.00% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.86M | 1.88% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.42M | 1.66% | +2.68% | Oct 2026 |
| Pictet-Biotech P USD | 1.82M | 0.88% | +0.38% | Jul 2026 |
| Polar Capital Biotech S Inc | 1.82M | 0.88% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.68M | 0.82% | +0.31% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.43M | 0.69% | -0.38% | Oct 2026 |
| Polar Capital Glb Healthcare Ord | 1.35M | 0.66% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 1.16M | 0.56% | 0.00% | Jul 2026 |
| Swedbank Robur Healthcare A | 1.07M | 0.52% | +36.00% | Oct 2026 |
| UTM IM GBP AXA Framlington Biotech | 1.01M | 0.49% | 0.00% | Sep 2026 |
| Principal SmallCap Growth I Instl | 937K | 0.46% | -0.09% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 920K | 0.45% | +0.02% | Aug 2026 |
| Vanguard Russell 2000 ETF | 890K | 0.43% | +1.33% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 829K | 0.40% | +0.24% | Oct 2026 |
| iShares Biotechnology ETF | 801K | 0.39% | -0.19% | Oct 2026 |
| Emerald Growth A | 799K | 0.39% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 720K | 0.35% | +4.46% | Sep 2026 |
| F/m Emerald Life Sciences Innovation ETF | 683K | 0.33% | 0.00% | Oct 2026 |
Top institutions holding SVRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| NEA Management Company, LLC | 24.5M | 11.91% | 0.00% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 17.6M | 8.56% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 14.7M | 7.17% | +7.32% | Jun 2026 |
| Nantahala Capital Management, LLC | 14.0M | 6.79% | +89.98% | Jun 2026 |
| Deerfield Management Co | 13.6M | 6.60% | 0.00% | Jun 2026 |
| BlackRock Inc | 12.5M | 6.08% | +10.66% | Jun 2026 |
| TCG Crossover Management, LLC | 12.4M | 6.01% | 0.00% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 9.72M | 4.73% | 0.00% | Jun 2026 |
| Polar Capital Holdings PLC | 9.54M | 4.64% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.93M | 3.86% | +1.91% | Jun 2026 |
| State Street Corp | 6.55M | 3.19% | -2.30% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 6.26M | 3.04% | +38.60% | Jun 2026 |
| RTW INVESTMENTS, LLC | 5.95M | 2.90% | 0.00% | Jun 2026 |
| Woodline Partners LP | 4.25M | 2.07% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 3.96M | 1.93% | +523.61% | Jun 2026 |
| Geode Capital Management, LLC | 3.87M | 1.88% | +7.72% | Jun 2026 |
| Spruce Street Capital LP | 3.45M | 1.68% | +2.05% | Jun 2026 |
| Rosalind Advisors, Inc. | 3.18M | 1.55% | -0.80% | Jun 2026 |
| Emerald Advisers, LLC | 3.14M | 1.53% | -0.23% | Sep 2026 |
| Pictet Asset Manangement SA | 2.76M | 1.34% | +21.43% | Jun 2026 |
Savara Inc company profile
- Company name
- Savara Inc
- Ticker
- SVRA.US
- Exchange
- USA Stocks
- Listed since
- Jun 1, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 70
- Fiscal year end
- December
- Address
- The Tannery Building, Yardley, PA, United States, 19067
- Phone
- (512) 614-1848
- Website
- savarapharma.com
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Savara Inc management
10- Mr. Matthew Pauls J.D., M.B.A.Chairman & CEO · born 1971
- Mr. Robert Matthew Lutz M.B.A.COO & CFO · born 1969
- Dr. Yasmine Wasfi M.D., Ph.D.Chief Medical Officer
- Ms. Kate McCabe J.D.Chief Legal Officer · born 1986
- Ms. Megan CarpenterChief People Officer
- Ms. Anne EricksonChief Business & Corporate Affairs Officer · born 1972
- Brian MaurerHead of Clinical Operations
- Mr. Charles LaPreeExecutive VP & Head of Global Regulatory Affairs
- Dr. Brian Robinson M.D.Executive Vice President of Global Medical Affairs
- Dr. Siddharth J. Advant Ph.D.Executive Vice President of Global Technical Operations